Circulating Asprosin Concentrations in Patients with Obesity and Carbohydrate Disturbances

Abstract

Asprosin is a fasting-induced glucogenic hormone, secreted by white adipose tissue in response to starvation. The aim of the current study was to determine the levels of asprosin in subjects from the entire spectrum of the carbohydrate metabolism. A total of 153 Causcasian subjects participated in this study: group 1, healthy volunteers; group 2, obese subjects without glycemic disturbances; group 3, subjects with prediabetes and group 4, patients with newly identified type 2 diabetes. Subject with body mass index≥30 kg/m2 and dysglycemia (prediabetes and diabetes) showed significantly high levels of asprosin (1.40 ng/ml [IQR=0.98–1.94]; 1.27 ng/ml [IQR=0.86–2.12]; 1.09 ng/ml [IQR=0.89–1.58]) compared to the control group (0.71 ng/ml [IQR=0.54–0.92]; p<0.001). Correlation analysis showed that serum asprosin also had significant positive associations with some anthropometric parameters, liver enzymes, fasting and post load glucose and insulin, LDL and triglycerides. Furthermore, we estimated a marked relationship between asprosin concentrations and intima media thickness of the common carotid artery as well as neuropathy disability and vibration sensitivity. The circulating asprosin levels for differentiating subjects with carbohydrate disturbances and those with obesity were determined by ROC analysis. The AUC for disturbances of the glucose metabolism was 0.672 (p<0.001; 95% CI=0.581–0.751) and for obesity AUC was 0.849 (p<0.001; 95% CI=0.785–0.919). Circulating asprosin could be used as a predictive factor for early carbohydrate disorders and might be a potential new therapeutic target for the treatment of dysglycemia and obesity. Further prospective studies are needed to confirm this observation.

Key words

obesity - metabolic syndrome - prediabetes - asprosin - adipokines

Publikationsverlauf

Eingereicht: 14. Oktober 2022

Angenommen nach Revision: 11. Februar 2023

Accepted Manuscript online:
11. Februar 2023

Artikel online veröffentlicht:
05. April 2023

• References

• 1 Sun H, Saeedi P, Karuranga S. et al. IDF diabetes atlas: global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. Diabetes Res Clin Pract 2022; 183: 109119
• 2 American Diabetes Association (2020) 2. Classification and diagnosis of diabetes: standards of medical care in diabetes-2020. Diabetes Care 2020; 43: S14-S31
• 3 Huang Y, Cai X, Mai W. et al. Association between prediabetes and risk of cardiovascular disease and all cause mortality: systematic review and meta-analysis. BMJ 2016; 355: i5953
• 4 Jin H, Jiang B, Tang J. et al. Serum visfatin concentrations in obese adolescents and its correlation with age and high-density lipoprotein cholesterol. Diabetes Res Clin Pract 2008; 79: 412-418
• 5 Romere C, Duerrschmid C, Bournat J. et al. Asprosin, a fasting-induced glucogenic protein hormone. Cell 2016; 165: 566-579
• 6 Li X, Liao M, Shen R. et al. Plasma asprosin levels are associated with glucose metabolism, lipid, and sex hormone profiles in females with metabolic-related diseases. Mediators Inflamm 2018; 7375294
• 7 Duerrschmid C, He Y, Wang C. et al. Asprosin is a centrally acting orexigenic hormone. Nat Med 2017; 23: 1444-1453
• 8 Zhang L, Chen C, Zhou N. et al. Circulating asprosin concentrations are increased in type 2 diabetes mellitus and independently associated with fasting glucose and triglyceride. Clin Chim Acta 2019; 489: 183-188
• 9 Wang Y, Qu H, Xiong X. et al. Plasma asprosin concentrations are increased in individuals with glucose dysregulation and correlated with insulin resistance and first-phase insulin secretion. Mediators Inflamm 2018; 9471583
• 10 Li X, Liao M, Shen R. et al. Plasma asprosin levels are associated with glucose metabolism, lipid, and sex hormone profiles in females with metabolic-related diseases. Mediators Inflamm 2018; 7375294
• 11 Greenhill C. Liver: Asprosin – new hormone involved in hepatic glucose release. Nat Rev Endocrinol 2016; 12: 312
• 12 Zhang X, Jiang H, Ma X. et al. Increased serum level and impaired response to glucose fluctuation of asprosin is associated with type 2 diabetes mellitus. J Diabetes Investig 2020; 11: 349-355
• 13 Kajimura S. Adipose tissue in 2016: Advances in the understanding of adipose tissue biology. Nat Rev Endocrinol 2017; 13: 69-70
• 14 Zhang L, Chen C, Zhou N. et al. Circulating asprosin concentrations are increased in type 2 diabetes mellitus and independently associated with fasting glucose and triglyceride. Clin Chim Acta 2019; 489: 183-188
• 15 Wang Y, Qu H, Xiong X. et al. Plasma asprosin concentrations are increased in individuals with glucose dysregulation and correlated with insulin resistance and first-phase insulin secretion. Mediators Inflamm 2018; 9471583
• 16 Li X, Liao M, Shen R. et al. Plasma asprosin levels are associated with glucose metabolism, lipid, and sex hormone profiles in females with metabolic-related diseases. Mediators Inflamm 2018; 7375294
• 17 Chiarelli F, Marcovecchio ML. Insulin resistance and obesity in childhood. Eur J Endocrinol 2008; 159: S 67-S74
• 18 Kahn SE, Hull RL, Utzschneider KM. Mechanisms linking obesity to insulin resistance and type 2 diabetes. Nature 2006; 444: 840-846
• 19 Wang M, Yin C, Wang L. et al. Serum asprosin concentrations are increased and associated with insulin resistance in children with obesity. Ann Nutr Metab 2019; 75: 205-212
• 20 Ugur K, Aydin S. Saliva and blood asprosin hormone concentration associated with obesity. Int J Endocrinol 2019; 2521096
• 21 Wang CY, Lin TA, Liu KH. et al. Serum asprosin levels and bariatric surgery outcomes in obese adults. Int J Obesity 2019; 43: 1019-1025
• 22 Jung TW, Kim HC, Kim HU. et al. Asprosin attenuates insulin signaling pathway through PKCδ-activated ER stress and inflammation in skeletal muscle. J Cell Physiol 2019; 234: 20888-20899
• 23 Long W, Xie X, Du C. et al. Decreased circulating levels of asprosin in obese children. Horm Res Paediatr 2019; 91: 271-277
• 24 Liu LJ, Kang YR, Xiao YF. Increased asprosin is associated with non-alcoholic fatty liver disease in children with obesity. World J Pediatr 2021; 17: 394-399
• 25 Ke F, Xue G, Jiang X. et al. Combination of asprosin and adiponectin as a novel marker for diagnosing non-alcoholic fatty liver disease. Cytokine 2020; 134: 155184
• 26 Lee T, Yun S, Jeong JH. et al. Asprosin impairs insulin secretion in response to glucose and viability through TLR4/JNK-mediated inflammation. Mol Cell Endocrinol 2019; 486: 96-104
• 27 Khan MA, Hashim MJ, Mustafa H. et al. Global epidemiology of ischemic heart disease: results from the global burden of disease study. Cureus 2020; 12: e9349
• 28 Acara AC, Bolatkale M, Kızıloğlu İ. et al. A novel biochemical marker for predicting the severity of ACS with unstable angina pectoris: Asprosin. Am J Emerg Med 2018; 36: 1504-1505
• 29 Güven C, Kafadar H. Evaluation of plasma asprosin concentration in patients with coronary artery disease. Braz J Cardiovasc Surg 2022; 37: 493-500
• 30 Moradi N, Fouani FZ, Vatannejad A. et al. Serum levels of asprosin in patients diagnosed with coronary artery disease (CAD): a case-control study. Lipids Health Dis 2021; 20: 88